Abstract
Background
Recent research has shown that the blood urea/creatinine ratio (BUN/Cr) rather than BUN or Cr alone can predict the prognosis of individuals with acute heart failure (AHF). The objective of this study was to estimate the urea-to creatinine serum ratio (BUN/Cr) in patients with acute decompensated heart failure (ADHF) and correlate the results with patient outcome, length of hospitalization, and mortality.
Results
Sixty ADHF patients were included and categorized into four groups; Group I: non-AKI with low BUN/Cr (n = 25); Group II: non-AKI with high BUN/Cr (n = 5); Group III: AKI with low BUN/Cr (n = 14); Group IV: AKI with high BUN/Cr (n = 16). Regarding urea and BUN levels, the first reading showed a considerable rise in urea and BUN levels in groups III and IV compared to group 1 and in group IV compared to groups I and III. Similar results were recorded in the second and third readings. Regarding the BUN/Cr ratio, the three readings revealed a significant elevation in group IV compared to groups I and II and in group IV compared to group III. Mortality was significantly higher in group IV compared to group I. Additionally, MACE was significantly more frequent in group IV compared to groups I and III. Multivariable logistic regression analysis revealed that hypertension, creatinine, and BUN were independent predictors of AKI.
Conclusions
BUN/Cr may predict prognosis in AHF patients since AHF with an elevated BUN/Cr is associated with a higher death rate.
Keywords: Urea-to-creatinine ratio, Acute heart failure, Acute kidney injury, Prognosis
Background
Heart failure (HF) symptoms or indicators can appear gradually or suddenly and are severe enough to demand immediate medical attention or an unplanned hospital stay. Patients with AHF need to be evaluated immediately, followed by the start or intensification of treatments. AHF is a major factor in hospital admissions for patients older than 65 and is linked to high death and readmission rates. Hospital mortality varies between 4 and 10% [1].
The AKI network defines acute kidney injury (AKI) as a rise in absolute serum creatinine of 0.3 mg/dl or a 1.5-fold increase in serum creatinine levels within 48 h [2].
In ADHF patients, AKI is not necessarily associated with mortality. Numerous investigations have demonstrated that elevations in serum creatinine brought on by the alleviation of congestion are not linked to long-term renal impairment or adverse effects [3]. To predict clinical outcomes in ADHF patients, it is crucial to understand the pathways that lead to AKI [3].
In patients with ADHF, renal impairment is a prevalent comorbidity. Higher blood BUN/Cr levels are linked to mortality in patients with concomitant renal impairment and HF [4]. The renal tubules are primarily traversed by creatinine, with little to no reabsorption. Serum creatinine levels are a primary indicator of glomerular filtration rate (GFR) when neurohormonal factors such as arginine, vasopressin, the sympathetic nervous system, and the renin–angiotensin–aldosterone system are all activated [5]. Elevated BUN/Cr, a proxy indicator of severe heart failure, may reveal AKI, which is linked to mortality [6].
When neurohormonal activity is present, creatinine travels through the glomerulus without being reabsorbed, whereas urea is disproportionately reabsorbed, raising the BUN/Cr ratio. Because of this, ADHF patients may experience more negative outcomes when their BUN/Cr is increased than when their creatinine or estimated GFR is elevated [7].
Therefore, the objective of this study was to assess the BUN/Cr in acute decompensated heart failure patients and correlate the results with the outcome, length of hospitalization, and mortality. Additionally, to determine whether clinical markers such as the BUN/Cr ratio or each alone can stratify the mortality risk associated with AKI.
Methods
This case–control study included 60 patients with acute decompensated heart failure (HFREF Or HFPEF according to EF% calculated by Echocardiography) admitted to the Cardiology Department at Specialized Medical Hospital, Mansoura University, from January to October 2021. Patients were classified into four groups according to AKI and level of Bun/Cr ratio; Group I: non-AKI with low BUN/Cr (n = 25); Group II: non-AKI with high BUN/Cr (n = 5); Group III: AKI with low BUN/Cr (n = 14); Group IV: AKI with high BUN/Cr (n = 16). Patients who were less than 18 years, pregnant, required renal replacement therapy, had known obstructive uropathy, or had known renal disease (e.g., polycystic kidney disease, glomerulonephritis) were excluded from the study.
All patients underwent a thorough medical history, chest X-ray, standard supine 12-lead electrocardiography, and echocardiography to detect structural or functional cardiac abnormalities. Blood samples were collected on admission (day one), after 48 h (day two), and before discharge (day three) to carry out laboratory investigations, including complete blood count (CBC), electrolytes (Na+, K+), urea, creatinine, BUN, BUN/Cr, and liver function tests. GFR was calculated by the Cockcroft–Gault formula. Also, coagulation profile (PT, PTT, and INR), cardiac enzymes (CK, CK-MB, and troponin), and arterial blood gases (ABGs) were performed.
Our patients did not take any nephrotoxic medications that may affect renal function and this point was thoroughly investigated during history taking.
We are so cautious for using fluid therapy during management of our patients. CVP cannot reflect volume status in heart failure so we use inotropes and diuretics in 59 patients. Furosemide is the only available diuretic. We used it as infusion for 18 patients in ICU, while the rest of them (41 patients) used it in dose of 10 mg iv/12 h and titrated the dose according to the response, potassium level and patient’s hemodynamics.
Statistical analysis
SPSS 22.0 for Windows was employed to examine all the data (SPSS Inc., Chicago, IL, USA). The Shapiro–Wilk test was used to assess normality. Frequencies and percentages were used to depict qualitative data. The Chi-square test was employed to determine how qualitative factors differed. Quantitative data were presented as mean ± SD (standard deviation) for parametric data. To compare normally distributed variables between more than two dependent groups, a one-way ANOVA test supplemented with an LSD post hoc test was utilized. ROC analysis was used to evaluate the diagnostic performance of different markers. The area under the curve (AUC) was used to assess the overall performance. The area under the curve of more than 50% represents acceptable performance, and the area of about 100% is the best performance. To determine how two quantitative variables are correlated, the Pearson correlation was used. Statistical comparisons were all two-tailed. The significance level was ≤ 0.05.
Results
Sixty AHF patients participated in the current research. The majority were males (71.7%). The mean age was 62.8 ± 10.4 years. Based on AKI and BUN/Cr, cases were classified into four groups. Baseline clinical characteristics, co-morbidities, complaints, presentation, HF etiology and treatment, ECG, and ECHO results are outlined in Table 1.
Table 1.
Baseline characteristics of the patients
| Parameter | (n = 60) | |
|---|---|---|
| Age | 62.8 ± 10.4 | |
| Gender | Male | 43 (71.7%) |
| Co-morbidities | ||
| DM | 30 (50.0%) | |
| HTN | 37 (61.7%) | |
| COPD | 8 (13.3%) | |
| VHD | 9 (15.0%) | |
| CAD | 14 (23.3%) | |
| Cardiomyopathy | 28 (46.7%) | |
| CLD | 6 (10.0%) | |
| AF | 13 (21.7%) | |
| Smoking | 22 (36.7%) | |
| CABG | 0 (0.0%) | |
| PCI | 4 (6.7%) | |
| Complain | ||
| Orthopnea | 47 (78.3%) | |
| Drowsiness | 8 (13.3%) | |
| Syncope | 10 (16.7%) | |
| Shortness of breath | 54 (90.0%) | |
| Palpitation | 10 (16.7%) | |
| Chest pain | 9 (15.0%) | |
| Presentation | ||
| Acute pulmonary edema | 26 (43.3%) | |
| Generalized anasarca | 17 (28.3%) | |
| Cardiogenic shock | 13 (21.7%) | |
| HF etiology | ||
| ACS | 14 (23.3%) | |
| Systemic infection | 8 (13.3%) | |
| Severe HTN | 4 (6.7%) | |
| Rapid AF | 10 (16.7%) | |
| Complete heart block | 7 (11.7%) | |
| Valvular heart disease | 8 (13.3%) | |
| Anemia | 2 (3.3%) | |
| Ventricular arrhythmia | 1 (1.7%) | |
| Acute exacerbation of chronic HF | 16 (26.7%) | |
| Treatment | ||
| ACEIS | 36 (60.0%) | |
| BB | 40 (66.7%) | |
| MRA | 36 (60.0%) | |
| Diuretics | 59 (98.3%) | |
| Inotropics | 20 (33.3%) | |
| Vasopressors | 13 (21.7%) | |
| ECG | ||
| ST–T wave changes | 22 (36.7%) | |
| AF | 16 (26.7%) | |
| Complete heart block | 7 (11.7%) | |
| Left BBB | 19 (31.7%) | |
| LVH | 1 (1.7%) | |
| ECHO | ||
| Median EF | 39.5 (18–55) | |
| SWMA | 25 (41.7%) | |
| Valvular disease | 45 (75.0%) | |
| Diastolic dysfunction | 10 (16.7%) | |
| Right-sided heart failure | 6 (10.0%) | |
Data are presented as mean ± SD and frequency (%). DM Diabetes mellitus, CAD Coronary artery disease, HTN Hypertension, COPD Chronic obstructive pulmonary disease, VHD Valvular heart disease, CLD Chronic liver disease, AF Atrial fibrillation
Table 2 shows significantly higher NYHA (4) in the AKI group versus the non-AKI group. SBP and DBP were significantly elevated in the non-AKI group compared to the AKI group. AKI patients had a significantly longer hospital stay than those without AKI. The non-AKI patients were more frequently treated by ACEIS, BB, and MRA, while the AKI group was more frequently treated by vasopressors. The AKI group had significantly higher creatinine, urea, BUN, and BUN/Cr in the first, second, and third readings than the non-AKI patients. GFR was significantly decreased in the first, second, and third readings in the AKI group versus the non-AKI group. K levels in the AKI group were substantially higher than in the non-AKI group (Table 2).
Table 2.
Comparison of NYHA, EF, blood pressure, treatment, and laboratory findings between patients with and without AKI
| Parameter | Non-AKI (n = 30) | AKI (n = 30) | P value |
|---|---|---|---|
| NYHA class D1 | |||
| 1 | 0 (0.0%) | 0 (0.0%) | 0.046 |
| 2 | 0 (0.0%) | 1 (3.3%) | |
| 3 | 12 (40.0%) | 4 (13.3%) | |
| 4 | 18 (60.0%) | 25 (83.3%) | |
| NYHA class D2 | |||
| 1 | 1 (3.3%) | 2 (6.7%) | 0.014 |
| 2 | 15 (50.0%) | 6 (20.0%) | |
| 3 | 13 (43.3%) | 13 (43.3%) | |
| 4 | 1 (3.3%) | 9 (30.0%) | |
| NYHA class D3 | |||
| 1 | 6 (20.0%) | 5 (16.7%) | 0.017 |
| 2 | 21 (70.0%) | 12 (40.0%) | |
| 3 | 3 (10.0%) | 7 (23.3%) | |
| 4 | 0 (0.0%) | 6 (20.0%) | |
| SBP* | 110.0 (60–210) | 100.0 (60–200) | 0.026 |
| DBP* | 70.0 (30–110) | 60.0 (40–100) | 0.032 |
| EF* | 40.0 (18–55) | 38.5 (19–55) | 0.486 |
| Length of stay in hospital* | 4.5 (3–18) | 8.5 (3–29) | < 0.001 |
| Treatment | |||
| ACEIS | 27 (90.0%) | 9 (30.0%) | < 0.001 |
| BB | 24 (80.0%) | 16 (53.3%) | 0.028 |
| MRA | 26 (86.7%) | 10 (33.3%) | < 0.001 |
| Diuretics | 30 (100.0%) | 29 (96.7%) | 1.00 |
| Inotropics | 8 (26.7%) | 12 (40.0%) | 0.273 |
| Vasopressors | 1 (3.3%) | 12 (40.0%) | 0.001 |
| HCT* | 35.5 ± 5.7 | 34.1 ± 6.3 | 0.373 |
| Creatinine (first reading) | 1.3 (0.7–2.9) | 2.5 (0.7–5.9) | < 0.001 |
| Creatinine (second reading) | 1.3 (1.0–3.0) | 3.0 (2.0–6.0) | < 0.001 |
| Creatinine (third reading) | 1.1 (0.8–1.9) | 2.8 (0.9–5.8) | < 0.001 |
| Urea (first reading) | 43.5 (22–88) | 98.0 (31–210) | < 0.001 |
| Urea (second reading) | 46.5 (28–157) | 136.5 (20–280) | < 0.001 |
| Urea (third reading) | 38.0 (21–95) | 100.0 (30–290) | < 0.001 |
| BUN (first reading) | 21.0 (10.2–65.4) | 45.7 (14.4–98.0) | < 0.001 |
| BUN (second reading) | 21.5 (13–73) | 63.5 (19–130) | < 0.001 |
| BUN (third reading) | 17.4 (10.5–44.3) | 46.0 (14–135.5) | < 0.001 |
| BUN/Cr (first reading) | 15.4 (10.5–41.4) | 21.1 (7.7–37.0) | 0.013 |
| BUN/Cr (second reading) | 15.0 (10–27) | 17.0 (8.0–37) | 0.048 |
| BUN/Cr (third reading) | 14.9 (11.6–26.2) | 19.5 (4.7–32.3) | 0.046 |
| GFR (first reading) | 76.8 (28.1–144) | 34.4 (14.1–167.0) | < 0.001 |
| GFR (second reading) | 66.0 (24–123) | 30.0 (12–73) | < 0.001 |
| GFR (third reading) | 83.0 (36–115) | 30.5 (10.1–110.2) | < 0.001 |
| Albumin | 3.9 (3.0–4.8) | 3.8 (1.2–4.5) | 0.047 |
| INR | 1.0 (1.0–2.0) | 1.0 (1.0–3.0) | 0.113 |
| Na | 124.0 (120–128) | 123.5 (120–128) | 0.759 |
| K | 4.0 (2.9–6.0) | 5.0 (3.0–6.0) | 0.016 |
Data are presented as mean ± SD, median (Min–Max), and frequency (%). P < 0.05 is considered significant. Glomerular filtration rate: GFR, BUN: Blood urea nitrogen, Cr: Creatinine, Na: Sodium, K: Potassium, INR: International normalized ratio
*Statistically significant, independent predictor
ROC analysis was used to determine the optimal cutoff levels for predicting AKI. The creatinine best cutoff value was 1.85, with an AUC of 0.811 (P < 0.001). The urea best cutoff value was 64.0, with an AUC of 0.866 (P < 0.001). The BUN best cutoff value was 31.5, with an AUC of 0.862 (P < 0.001). The BUN/Cr best cutoff value was 17.4, with an AUC of 0.687 (P = 0.013) (Fig. 1).
Fig. 1.
ROC curve analysis
Table 3 shows a significant increase in NYHA class 4 on day 1 in group IV compared to group I and on days 2 and 3 in group IV compared to groups I and III. There was a significant decrease in SBP and DBP in group IV compared to groups I and III. The length of hospital stay was significantly higher in groups III and IV compared to group 1. Additionally, drug use significantly differed among the four groups (Table 3).
Table 3.
Comparison of NYHA, EF, blood pressure, and treatment among the studied groups regarding the presence and absence of AKI with low or high BUN/Cr
| Parameter | Group 1 (n = 25) | Group 2 (n = 5) | Group 3 (n = 14) | Group 4 (n = 16) | P value |
|---|---|---|---|---|---|
| NYHA class D1 | |||||
| 1 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
P = 0.135 P3 = 0.034 |
| 2 | 0 (0.0%) | 0 (0.0%) | 1(7.1%) | 0 (0.0%) | |
| 3 | 11 (44.0%) | 1 (20.0%) | 2 (14.3%) | 2 (12.5%) | |
| 4 | 14 (56.0%) | 4 (80.0%) | 11 (78.6%) | 14 (87.5%) | |
| NYHA class D2 | |||||
| 1 | 1 (4.0%) | 0 (0.0%) | 2 (14.3%) | 0 (0.0%) |
P = 0.004 P3 = 0.001 P6 = 0.017 |
| 2 | 13 (52.0%) | 2 (40.0%) | 5 (35.7%) | 1 (6.2%) | |
| 3 | 10 (40.0%) | 3 (60.0%) | 6 (42.9%) | 7 (43.8%) | |
| 4 | 1 (4.0%) | 0 (0.0%) | 1 (7.1%) | 8 (50.0%) | |
| NYHA class D3 | |||||
| 1 | 6 (24.0%) | 0 (0.0%) | 4 (28.7%) | 1 (6.2%) |
P = 0.005 P3 ≤ 0.001 P6 = 0.025 |
| 2 | 17 (68.0%) | 4 (80.0%) | 8 (57.1%) | 4 (25.0%) | |
| 3 | 2 (8.0%) | 1 (20.0%) | 1 (7.1%) | 6 (37.5%) | |
| 4 | 0 (0.0%) | 0 (0.0%) | 1 (7.1%) | 5 (31.3%) | |
| SBP* | 120.0 (60–210) | 100.0 (80–140) | 115.0 (70–200) | 80.0 (60–160) |
P = 0.332 P3 = 0.001 P6 = 0.010 |
| DBP* | 70.0 (30–110) | 70.0 (50–90) | 70.0 (40–100) | 55.0 (40–100) |
P = 0.362 P3 = 0.001 P6 = 0.004 |
| EF* | 40.0 (18–55) | 40.0 (27–50) | 39.5 (20–55) | 38.0 (19–55) | 0.988 |
| Length of hospital stay * | 4.0 (3–18) | 8.0 (7–18) | 8.0 (3–23) | 10.5 (7–29) |
P ≤ 0.001 P1 = 0.002 P2 = 0.010 P3 ≤ 0.001 |
| ACEIS | 23 (92.0%) | 4 (80.0%) | 5 (35.7%) | 4 (25.0%) |
P ≤ 0.001 P2 ≤ 0.001 P3 ≤ 0.001 P5 = 0.027 |
| BB | 22 (88.0%) | 2 (40.0%) | 9 (64.3%) | 7 (43.8%) |
P = 0.015 P1 = 0.014 P3 = 0.002 |
| MRA | 23 (92.0%) | 3 (60.0%) | 6 (42.9%) | 4 (25.0%) |
P ≤ 0.001 P2 ≤ 0.001 P3 ≤ 0.001 |
| Diuretics | 25 (100.0%) | 5 (100.0%) | 13 (92.3%) | 16 (100.0%) | 0.342 |
| Inotropics | 3 (12.0%) | 5 (100.0%) | 3 (21.4%) | 9 (56.2%) |
P ≤ 0.001 P1 ≤ 0.001 P3 = 0.002 P4 = 0.002 |
| Vasopressors | 0 (0.0%) | 1 (20.0%) | 3 (21.4%) | 9 (56.2%) |
P ≤ 0.001 P1 ≤ 0.001 P2 = 0.015 P3 ≤ 0.001 |
Data are presented as mean ± SD, median (Min–Max), and frequency (%). P < 0.05 is considered significant. DBP: Diastolic blood pressure, SBP: Systolic blood pressure, EF: Ejection fraction, ACEIS: Angiotensin-converting enzymes inhibitors, BB: Beta blockers, MRA: Mineralocorticoid receptor antagonists. P between 4 groups. P1 between group 1 and group 2, P2 between group 1 and group 3. P3 between group 1 and group 4. P4 between group 2 and group 3. P5 between group 2 and group 4. P6 between group 3 and group 4
*Statistically significant, independent predictor
Table 4 demonstrates a significant increase in creatinine levels at the first and third readings in groups III and IV compared to group I, and in group IV compared to group I. Similar results were recorded in the second reading.
Table 4.
Comparison of laboratory parameters among patient group regarding presence and absence of AKI with low or high BUN/Cr
| Parameter | Group 1 (n = 25) | Group 2 (n = 5) | Group 3 (n = 14) | Group 4 (n = 16) | P value |
|---|---|---|---|---|---|
| Hb* | 12.5 ± 2.22 | 12.1 ± 2.23 | 11.9 ± 3.38 | 11.8 ± 1.72 | 0.816 |
| HCT* | 35.7 ± 5.69 | 34.6 ± 6.65 | 34.14 ± 8.37 | 34.13 ± 4.03 | 0.821 |
| Creatinine (1st reading) | 1.3 (0.8–2.9) | 1.2 (0.7–2.3) | 2.8 (0.7–5.9) | 2.1 (1.3–4.3) |
P = 0.058 P2 = 0.026 P3 ≤ 0.001 P5 = 0.025 |
| Creatinine (2nd reading) | 1.0 (1.0–2.0) | 2.0 (1.0–3.0) | 3.5 (2.0–6.0) | 3.0 (2.0–6.0) |
P ≤ 0.001 P2 ≤ 0.001 P3 ≤ 0.001 P4 = 0.034 P5 = 0.015 |
| Creatinine (3rd reading) | 1.1 (0.9–1.8) | 1.6 (0.8–1.9) | 2.6 (0.9–5.1) | 3.05 (1.2–5.8) |
P = 0.004 P2 = 0.001 P3 ≤ 0.001 P5 = 0.008 |
| Urea (1st reading) | 42.0 (22–70) | 48.0 (28.1–88) | 90.0 (31–170) | 115.0 (68–210) |
P = 0.019 P2 = 0.006 P3 ≤ 0.001 P5 ≤ 0.001 P6 = 0.017 |
| Urea (2nd reading) | 44.0 (28–82) | 85.0 (38.0–157.0) | 93.5 (41–195) | 150.0 (20–280) |
P ≤ 0.001 P1 = 0.013 P2 ≤ 0.001 P3 ≤ 0.001 P5 = 0.050 P6 = 0.007 |
| Urea (3rd reading) | 35.0 (21–67) | 70.0 (37–95) | 74.0 (30–140) | 155.0 (52–290) |
P = 0.003 P1 = 0.004 P2 = 0.005 P3 ≤ 0.001 P5 = 0.004 P6 = 0.001 |
| BUN (1st reading) | 20.0 (10.2–32.7) | 37.3 (14–65.4) | 42.0 (14.4–79.0) | 53.5 (32.0–98.0) |
P = 0.013 P2 = 0.006 P3 ≤ 0.001 P5 = 0.019 P6 = 0.017 |
| BUN (2nd reading) | 20.0 (13–32) | 40.0 (18–73) | 43.5 (19–91) | 70.0 (36–130) |
P ≤ 0.001 P1 = 0.013 P2 ≤ 0.001 P3 ≤ 0.001 P5 = 0.015 P6 = 0.002 |
| BUN (3rd reading) | 16.3 (10.5–31.3) | 32.0 (17.2–44.3) | 34.5 (14–65) | 72 (22.5–135.5) |
P = 0.002 P1 = 0.003 P2 = 0.005 P3 ≤ 0.001 P5 = 0.004 P6 = 0.001 |
| BUN/Cr (1st reading) | 15.0 (10.5–19.6) | 24.0 (18.6–41.4) | 13.6 (7.7–26.0) | 23.7 (15.5–37.0) |
P = 0.005 P1 ≤ 0.001 P3 ≤ 0.001 P4 = 0.007 P6 ≤ 0.001 |
| BUN/Cr (2nd reading) | 15.0 (10.0–20.0) | 21.0 (17.0–27.0) | 12.5 (8.0–18.0) | 23.5 (15.0–37.0) |
P ≤ 0.001 P1 ≤ 0.001 P3 ≤ 0.001 P4 ≤ 0.001 P6 ≤ 0.001 |
| BUN/Cr (3rd reading) | 14.3 (11.6–24.1) | 21.5 (18.4–26.2) | 13.9 (4.7–17.1) | 22.1 (18.5–32.3) |
P = 0.002 P1 ≤ 0.001 P3 ≤ 0.001 P4 ≤ 0.001 P6 ≤ 0.001 |
| GFR (1st reading) | 76.7 (29.3–127.0) | 104.0 (28.1–144) | 29.0 (15–167) | 40.5 (14.1–102) |
P = 0.041 P2 = 0.017 P3 ≤ 0.001 P5 = 0.025 |
| GFR (2nd reading) | 66.0 (37–115) | 52.0 (24–123) | 25.0 (14–68) | 31.0 (12–73) |
P = 0.001 P2 ≤ 0.001 P3 ≤ 0.001 P5 = 0.032 |
| GFR (3rd reading) | 82.0 (47.5–115) | 85.0 (36.0–114) | 32.5 (17.1–106) | 27.0 (10.1–110.2) |
P = 0.005 P2 = 0.001 P3 ≤ 0.001 P4 = 0.044 P5 = 0.015 |
| Albumin | 3.9 (3–4.8) | 3.8 (3.2–4.5) | 3.8 (1.2–4.5) | 3.5 (2.9–4.1) |
P = 0.619 P3 = 0.017 |
| INR | 1.0 (1–2) | 1.0 (1–2) | 1.0 (1–2) | 1.0 (1–3) | 0.278 |
| Na | 124.0 (120–128) | 124.0 (120–128) | 123.5 (120–126) | 123.5 (120–128) | 0.940 |
| K | 4.0 (2.9–6.0) | 4.0 (4–6) | 5.0 (4–6) | 4.5 (3–6) |
P = 0.009 P2 = 0.008 |
Data are presented as mean ± SD, median (Min–Max), and frequency (%). P < 0.05 is considered significant. GFR: Glomerular filtration rate, K: Potassium, Cr: Creatinine, Na: Sodium, BUN: Blood urea nitrogen, INR: International normalized ratio
*Statistically significant, independent predictor
Regarding urea and BUN levels, the first reading revealed a significant increase in groups III and IV compared to group I, and in group IV compared to groups I and III. A similar pattern was reported in the second and third urea and BUN readings.
Regarding the BUN/Cr ratio, the three readings revealed a significant elevation in group IV compared to groups I and II, and in group IV compared to group III. Additionally, the GFR significantly declined in groups III and IV compared to group I.
Albumin level significantly declined in group IV compared to group I, while K level was significantly higher in group III compared to group 1 (Table 4).
Table 5 shows that death was significantly more frequent in group IV than in group I, while MACE was significantly more frequent in group IV compared to groups I and III (Table 5).
Table 5.
Comparison of outcomes among the four groups regarding the presence and absence of AKI with low or high BUN/Cr
| Parameter | Group 1 (n = 25) | Group 2 (n = 5) | Group 3 (n = 14) | Group 4 (n = 16) | P value |
|---|---|---|---|---|---|
| Death | 1 (4.0%) | 1 (20.0%) | 3 (21.4%) | 9 (56.2%) |
P = 0.001 P3 ≤ 0.001 |
| HD | 0 (0.0%) | 0 (0.0%) | 1 (7.1%) | 2 (12.5%) | 0.307 |
| MACE | 1 (4.0%) | 2 (40.0%) | 1 (7.1%) | 7 (43.8%) |
P = 0.004 P1 = 0.014 P3 = 0.001 P6 = 0.026 |
HD: Hemodialysis, MACE: Major adverse cardiac event. One-way ANOVA*, Chi-square test. P between 4 groups. P1 between group 1 and group 2, P2 between group 1 and group 3. P3 between group 1 and group 4. P4 between group 2 and group 3. P5 between group 2 and group 4. P6 between group 3 and group 4
The AKI risk was predicted using logistic regression analysis. The covariates included HTN, SBP, DBP, creatinine, urea, BUN, BUN/Cr, GFR, albumin, and K. Only HTN, creatinine, and BUN were considered independent AKI predictors after the inclusion of significant factors at the univariate level in a multivariable analysis (Table 6).
Table 6.
Regression analysis for prediction of AKI
| Univariable | Multivariable | |||||||
|---|---|---|---|---|---|---|---|---|
| P | OR | 95% CI | P | OR | 95% CI | |||
| History of HTN | 0.019 | 3.755 | 1.239 | 11.385 | 0.048 | 7.135 | 1.017 | 50.059 |
| SBP | 0.037 | 0.985 | 0.970 | 0.999 | 0.980 | 0.999 | 0.944 | 1.058 |
| DBP | 0.038 | 0.972 | 0.947 | 0.999 | 0.861 | 0.990 | 0.890 | 1.103 |
| Creatinine | 0.001 | 5.758 | 2.040 | 16.248 | 0.046 | 2.594 | 1.084 | 30.269 |
| Urea | < 0.001 | 1.064 | 1.032 | 1.097 | 0.308 | 1.095 | 0.919 | 1.305 |
| BUN | < 0.001 | 1.105 | 1.050 | 1.163 | 0.039 | 1.044 | 1.021 | 1.385 |
| BUN/Cr | 0.030 | 1.103 | 1.009 | 1.206 | 0.996 | 1.001 | 0.769 | 1.302 |
| GFR | 0.003 | 0.972 | 0.954 | 0.990 | 0.186 | 0.990 | 0.968 | 1.063 |
| Albumin | 0.053 | 0.334 | 0.110 | 1.015 | – | – | – | – |
| K | 0.040 | 2.004 | 1.034 | 3.883 | 0.128 | 2.462 | 0.771 | 7.865 |
OR: odds ratio; CI, confidence interval; logistic regression analysis was used. P < 0.05 indicates statistical significance. K: Potassium, HTN: Hypertension, DBP: Diastolic blood pressure, SBP: Systolic blood pressure, Na: Sodium, BUN: Urea nitrogen, BUN/Cr: Urea/creatinine ratio
Discussion
The current study aimed to investigate if clinical markers such as the BUN/Cr ratio, BUN, or creatinine can stratify the AKI mortality risk in ADHF patients and whether these markers are associated with the outcome, length of hospital stay, and death.
This study observed a significant increase in NYHA class 4 on day 1 in group IV compared to group I and on days 2 and 3 in group IV compared to groups I and III. There was a substantial decrease in SBP and DBP in group IV compared to groups I and III. In line, Takaya et al. [2] reported that compared to the other groups, blood pressure (systolic and diastolic) is lower in group 4, and it is usually treated with IV dopamine and dobutamine therapy.
Our study demonstrated a significant increase in creatinine at the first and third readings in groups III and IV compared to group I. Similar findings were observed in the second reading, with a significant elevation in group III compared to group I.
First readings of urea and BUN showed a significant rise in groups III and IV compared to group I, and in group IV compared to groups I and III. Comparable results were reported in the second and third readings.
The BUN/Cr ratio readings demonstrated a significant rise in group IV compared to groups I, II, and III. There was a substantial decline in GFR in groups III and IV compared to group I in the three GFR readings. These results are compatible with Takaya et al. [2], who reported that AKI patients with high BUN/Cr have lower GFR but higher BUN, creatinine, and BUN/Cr levels than the other groups.
Higher creatinine levels may be due to either permanent renal damage or congestion relief. On the other hand, urea excretion is decreased by renal vasoconstriction and decreased GFR caused by neurohormonal components, such as the sympathetic nervous system and renin–angiotensin–aldosterone system [8, 9].
Additionally, flow- and concentration-dependent urea absorption is increased by neurohormonal activity [10]. Low cardiac output causes arterial underfilling that induces arginine vasopressin production, encouraging urea reabsorption [10]. While urea is disproportionately reabsorbed during neurohormonal activation, causing an increased BUN/Cr ratio, the glomerulus freely filters creatinine, which is not reabsorbed. [11]. Therefore, a higher BUN/Cr more accurately represents neurohormonal activity than a higher creatinine or a lower estimated GFR [2].
In regression analysis for predicting AKI, only HTN, creatinine, and BUN were independent predictors of AKI. Takaya et al. [2] observed that BUN, creatinine, and intravenous dobutamine are independent risk factors for AKI. Additionally, Tung et al. [12] stated that age, GFR, WBCS, Hb, BUN, creatinine, B-type natriuretic peptide, Cystatin C, and neutrophil gelatinase-associated lipocalin are associated with AKI in the univariate analysis. However, no variable remained significant after multivariate analysis.
The current study has some limitations: the first is the observational nature of the study. Second, the non-neurohormonal factors affecting the BUN/Cr ratio include a high-protein diet, cachexia, and muscular atrophy; however, these elements were not examined in this investigation. Third, the time interval for serum creatinine tests was not just 48 h since the timing of laboratory measurements was allowed at the treating physicians' discretion, thereby underestimating the incidence of AKI. Finally, the AKI network criteria use urine output and serum creatinine to define AKI; however, we only used serum creatinine. Therefore, these results need to be supported by data from sizable, well-planned trials to advance our understanding of the BUN/Cr in AHF patients.
Conclusions
In ADHF patients, higher mortality risk is associated with AKI and an increased BUN/Cr on admission, but not with BUN or creatinine alone. Our results imply that the BUN/Cr on admission determines AKI prognosis and is helpful for risk stratifying. AKI risk assessment, which can be completed on admission, may help decide whether to continue decongestion therapy for ADHF patients with low BUN/Cr despite elevated creatinine levels as opposed to considering additional ADHF treatment options in AKI patients with a high BUN/Cr. Additional research is required to verify these results and explore therapeutic approaches to enhance clinical outcomes in ADHF patients.
Acknowledgements
None
Abbreviations
- AHF
Acute heart failure
- BUN/Cr
Urea-to-creatinine serum ratio
- AKI
Acute kidney infarction
- HF
Heart failure
- GFR
GFR
- ROC
Receiver operating characteristic curve
- ADHF
Acute decompensated heart failure
- DM
Diabetes mellitus
- HTN
Hypertension
- COPD
Chronic obstructive pulmonary disease
- VHD
Valvular heart disease
- CAD
Coronary artery disease
- CLD
Chronic liver disease
- AF
Atrial fibrillation
- NYHA
New York Heart Association
- SBP
Systolic blood pressure
- DBP
Diastolic blood pressure
- EF
Ejection fraction
- INR
International normalized ratio
- Na
Sodium
- K
Potassium
- ACEIS
Angiotensin-converting enzymes inhibitors
- BB
Beta blockers
- MRA
Mineralocorticoid receptor antagonists
- HD
Hemodialysis
- MACE
Major adverse cardiac event
Author contributions
GFEG and SME conceived and supervised the study; AHHE and ARMS were responsible for data collection. ARMS and SME analyzed and interpreted the data. All authors provided comments on the manuscript at various stages of development. All authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
Data and material are available on a reasonable request from the author.
Declarations
Ethical approval and consent to participate
It was approved by the ethics committee of Faculty of medicine, Tanta University, and it was started at October 2019 and ended by October 2021. An informed written consent was obtained from the participants.
Consent for publication
All authors give their consent for publication in the journal.
Informed consent
Written informed consent to publish this information was obtained from study participants.
Competing interests
The authors declare no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Miró Ò, García Sarasola A, Fuenzalida C, Calderón S, Jacob J, Aguirre A, et al. Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. Eur J Heart Fail. 2019;21(10):1231–1244. doi: 10.1002/ejhf.1567. [DOI] [PubMed] [Google Scholar]
- 2.Takaya Y, Yoshihara F, Yokoyama H, Kanzaki H, Kitakaze M, Goto Y, et al. Risk stratification of acute kidney injury using the blood urea nitrogen/creatinine ratio in patients with acute decompensated heart failure. Circ J. 2015;79(7):1520–1525. doi: 10.1253/circj.CJ-14-1360. [DOI] [PubMed] [Google Scholar]
- 3.Takaya Y, Yoshihara F, Yokoyama H, Kanzaki H, Kitakaze M, Goto Y, et al. Impact of onset time of acute kidney injury on outcomes in patients with acute decompensated heart failure. Heart Vessels. 2016;31(1):60–65. doi: 10.1007/s00380-014-0572-x. [DOI] [PubMed] [Google Scholar]
- 4.Testani JM, Coca SG, Shannon RP, Kimmel SE, Cappola TP. Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials. Eur J Heart Fail. 2011;13(11):1224–1230. doi: 10.1093/eurjhf/hfr123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584–603. doi: 10.1002/ejhf.1697. [DOI] [PubMed] [Google Scholar]
- 6.Brisco MA, Coca SG, Chen J, Owens AT, McCauley BD, Kimmel SE, et al. Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. Circ Heart Fail. 2013;6(2):233–239. doi: 10.1161/circheartfailure.112.968230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Miura M, Sakata Y, Nochioka K, Takahashi J, Takada T, Miyata S, et al. Prognostic impact of blood urea nitrogen changes during hospitalization in patients with acute heart failure syndrome. Circ J. 2013;77(5):1221–1228. doi: 10.1253/circj.cj-12-1390. [DOI] [PubMed] [Google Scholar]
- 8.Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30–38. doi: 10.1038/nrcardio.2016.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Fu K, Hu Y, Zhang H, Wang C, Lin Z, Lu H, et al. Insights of worsening renal function in type 1 cardiorenal syndrome: from the pathogenesis, Biomarkers to Treatment. Front Cardiovasc Med. 2021;8:760152. doi: 10.3389/fcvm.2021.760152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–e878. doi: 10.1161/CIR.0000000000000664. [DOI] [PubMed] [Google Scholar]
- 11.Qian H, Tang C, Yan G. Predictive value of blood urea nitrogen/creatinine ratio in the long-term prognosis of patients with acute myocardial infarction complicated with acute heart failure. Medicine (Baltimore) 2019;98(11):e14845. doi: 10.1097/md.0000000000014845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Tung Y-C, Chang C-H, Chen Y-C, Chu P-H. Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. PLoS ONE. 2015;10(4):e0125282. doi: 10.1371/journal.pone.0125282. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data and material are available on a reasonable request from the author.